AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$14.88
-0.24 (-1.59%)
▼
5d:
-9.1%
30d:
-0.07%
90d:
+0.68%
HOLD
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Jul 29, 2026
17d
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $14.88, which is considered slightly low relative to its 30-day fair value range of $14.61 to $16.10. From a valuation perspective, the stock is trading at a discount (Forward PE: -744.0) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, AMRN is in a uptrend. The price is currently testing key support at $14.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRN is in a uptrend. The price is currently testing key support at $14.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.61 -
$16.10
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 19.4% above Wall St target ($12.00)
- CAUTION: Recommendation downgraded due to -9.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$14.61 -
$16.10
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$14.60
Resistance Level
$16.79
Current Trend
Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-744.00
Wall Street Target
$12.00
(-19.4%)
Revenue Growth (YoY)
7.4%
Earnings Growth (YoY)
-94.2%
Profit Margin
-15.5%
PE vs Historical
-744.0 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: July 11, 2026 8:32 AM ET
Data refreshes hourly during market hours. Next update: 9:32 AM
Data refreshes hourly during market hours. Next update: 9:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1220 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 65 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$355 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$256 | 59 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 57 HOLD |
